Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Guilford Hurst

Clinical Nurse Specialist, Psychiatric/Mental Health, Adult Lewes, DE Clinical Nurse Specialist

NPI 1467779256 CMS profile 10694855

33712 Wescoats Rd Unit 4, Lewes, DE 19958

Open in the dashboard

General payments

$42,255

316 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Guilford Hurst of Lewes, DE is reported in the CMS Open Payments database as having received $42,255 across 316 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,982 58
2024 General $9,551 43
2023 General $12,693 58
2022 General $1,437 74
2021 General $5,592 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Guilford Hurst
  • Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Guilford Hurst were reported at $12,982. Among 197 Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles paid that year, the median was $174 and the middle half received between $71 and $653.

Show as a table
Year Guilford Hurst Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $5,592 $152 $38–$472 $132
2022 $1,437 $172 $73–$546 $149
2023 $12,693 $156 $56–$560 $160
2024 $9,551 $158 $39–$521 $164
2025 $12,982 $174 $71–$653 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $34,083 91 payments
  2. AbbVie, Inc. $4,929 47 payments
  3. Otsuka America Pharmaceutical, Inc. $561 32 payments
  4. Janssen Pharmaceuticals, Inc $487 20 payments
  5. ITI, Inc. $475 23 payments
  6. Avanir Pharmaceuticals, Inc. $340 24 payments
  7. Teva Pharmaceuticals USA, Inc. $314 17 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $262 14 payments
  9. Neurocrine Biosciences, Inc. $210 11 payments
  10. E.R. Squibb & Sons, L.L.C. $162 13 payments
  11. Other $433 24 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,095 23 payments
  2. Food and Beverage $6,066 283 payments
  3. Consulting Fee $4,380 2 payments
  4. Travel and Lodging $2,715 8 payments
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $34,030 88 payments
  2. LYBALVI Cns $33,647 71 payments
  3. LYBALVI Cns $33,385 62 payments
  4. LYBALVI Cns $33,385 62 payments
  5. VRAYLAR $4,898 45 payments
  6. ARISTADA Cns $660 27 payments
  7. ARISTADA Cns $660 27 payments
  8. CAPLYTA $403 20 payments
  9. ARISTADA Cns $399 18 payments
  10. ARISTADA Cns $399 18 payments
  11. Other $3,590 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

5,754

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$884,422

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

19.4%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 71 $147,036
Lybalvi Olanzapine/Samidorphan Malate Brand 82 $144,967
Ingrezza Valbenazine Tosylate Brand 16 $135,435
Invega Sustenna Paliperidone Palmitate Brand 39 $106,434
Austedo Deutetrabenazine Brand 11 $42,440
Aristada Aripiprazole Lauroxil Brand 13 $31,141
Vraylar Cariprazine Hcl Brand 19 $30,640
Lupron Depot Leuprolide Acetate Brand 13 $27,456
Trintellix Vortioxetine Hydrobromide Brand 17 $18,012
Divalproex Sodium Er Divalproex Sodium Brand 163 $15,016

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$244,704

Medicare's payments for the services billed

Medicare patients

438

Average age 66

Services billed

3,006

270 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Depression 67%
Arthritis 45%
Ischemic heart disease 30%
Diabetes 29%
Osteoporosis 18%
Chronic kidney disease 17%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYBALVI
  • Alkermes, Inc. $9,022
$9,022 82 —
ARISTADA
  • Alkermes, Inc. $145
$145 13 —
CAPLYTA
  • ITI, Inc. $67
$67 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $51
$51 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $39
$39 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health, Adult in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record